Clinic Software← All companies
ActoKine Therapeutics
StageConflicting reports: company website indicates seed funding from angel investors, while other sources describe it as unfunded.
RaisedConflicting reports: described as receiving seed funding from angels but also reported as having raised no funding.
Employees2
LocationNewton, MA
Founders
- Grace Wong, PhD — Founder, CEO (Asia & USA), and Chief Scientific Officer
Investors
Angel investors
News
- ActoKine Therapeutics - 2026 Company Profile, Team & Competitors · 2026-03-19T00:00:00.000Z
- Massachusetts Biotech Employers · 2025-01-14T00:00:00.000Z
- A startup banks $66M to pursue ‘inclusive precision medicine’ | BioPharma Dive · 2025-06-18T07:00:00.000Z
- Actio Biosciences Secures $66 Million Series B Financing to Advance Genetics-Driven Pipeline of Small Molecule Therapeutics for Rare and Common Diseases · 2025-06-18T00:00:00.000Z
- Actio Biosciences Announces Initiation of KYRON Phase 1b/2 Trial of ABS-1230 for the Treatment of KCNT1-Related Epilepsy and Acceptance into FDA’s Rare Disease Evidence Principles Process • Actio Biosciences · 2026-05-08T04:34:53.000Z
- Actio Biosciences Announces First Participant Dosed in Phase 1 Clinical Trial of ABS-1230, a KCNT1 Inhibitor for the Treatment of KCNT1-Related Epilepsy • Actio Biosciences · 2025-09-23T12:43:17.000Z
